Key Points
- Insider buying: Oxford Biomedica director Roch Doliveux purchased 20,250 shares at GBX 505 each, for a total investment of £102,262.50.
- Financial performance remains weak: The company reported quarterly EPS of negative GBX 30.39, alongside a negative net margin of 23.23% and negative return on equity of 54.51%.
- Analysts are moderately bullish: Four analysts rate the stock Buy and one rates it Hold, producing a “Moderate Buy” consensus and an average price target of GBX 580.85 versus a recent opening price of GBX 492.
Oxford Biomedica plc (LON:OXB - Get Free Report) insider Roch Doliveux acquired 20,250 shares of Oxford Biomedica stock in a transaction that occurred on Wednesday, September 23rd. The shares were purchased at an average price of GBX 505 per share, with a total value of £102,262.50.
Oxford Biomedica Trading Up 2.3%
Shares of LON:OXB opened at GBX 492 on Friday. The stock has a market capitalization of £595.56 million, a price-to-earnings ratio of -18.28 and a beta of 1.09. The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21. The stock's 50-day simple moving average is GBX 509.34 and its two-hundred day simple moving average is GBX 575.10. Oxford Biomedica plc has a 52-week low of GBX 420 and a 52-week high of GBX 952.
Oxford Biomedica (LON:OXB - Get Free Report) last released its quarterly earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. Analysts expect that Oxford Biomedica plc will post -31.0799998 EPS for the current year.
Analyst Upgrades and Downgrades
OXB has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 595 price target on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Royal Bank Of Canada reissued an "outperform" rating and issued a GBX 900 target price on shares of Oxford Biomedica in a report on Tuesday, September 1st. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 8.27 price target on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Oxford Biomedica currently has an average rating of "Moderate Buy" and an average price target of GBX 580.85.
View Our Latest Analysis on Oxford Biomedica
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
